$KRTL Holding Group Reports 2024 Financial Results and Advances Toward International Pharmaceutical Integration
https://www.otcmarkets.com/stock/KRTL/news/KR...?id=471918
KRTL Holding Group, Inc. (OTC: KRTL), a diversified holding company with subsidiaries engaged in pharmaceutical consulting, regulatory compliance, and international commercialization, today reported its financial results for the year ended December 31, 2024, and outlined its strategic roadmap for 2025.
Operational & Strategic Milestones
Strategic Merger Initiated: KRTL Biotech signed a Memorandum of Understanding (MOU) with Bolivia-based Industria QuÃÂmico Farmacéutica Sigma Corp. S.R.L., initiating a formal international merger process and integrated manufacturing expansion.
Regulatory Compliance Strengthened: Maintained FDA registration for KRTL Biotech's operational platform and implemented a robust Quality Management System (QMS), aligning with international regulatory standards.
Market Expansion Efforts: Attracted interest from U.S. and South American pharmaceutical manufacturers seeking entry to the U.S. via KRTL Biotech's compliance infrastructure for faster, regulation-aligned distribution.
Enhanced Internal Capabilities: Expanded internal teams in legal, accounting, and strategic advisory to support governance, licensing, and market entry advisory services.
Looking Ahead â KRTL Strengthens Global Infrastructure
In 2025, KRTL continues to evolve with international production capabilities and scalable regulatory support. The Company's FDA-anchored regulatory foundation, expanding QMS, and growing pharmaceutical network position it to offer high-value services and products, including:
U.S. Market Entry Support: Assisting foreign manufacturers in leveraging KRTL's FDA-registered subsidiary and quality systems for streamlined entry into the U.S. market.
API Sourcing and Oversight: Managing formulation, labeling, and sourcing in partnership with GMP-certified manufacturers in the U.S. and South America, supported by bilateral logistics frameworks and FDA documentation protocols.
Regulatory Consulting & Licensing: Providing strategic regulatory guidance and licensing support to early-stage pharmaceutical and nutraceutical companies, ensuring 21 CFR, DEA, and international compliance alignment.
Revenue-Sharing & Commercialization: Facilitating product commercialization and revenue-sharing partnerships under the KRTL umbrella, including current product launches and licensing structures.
CEO Cesar Herrera commented: "KRTL is creating new opportunities for partners, international consultants, and global investors by actively identifying undervalued assets and leveraging the company's expertise in regulatory and operational frameworks. The company continues to pursue mergers and acquisitions, strategically evaluating and stacking candidates that align with its long-term growth vision. Recent achievements, including FDA registration, implementation of a Quality Management System (QMS), and the merger with SIGMA, validate KRTL's unique infrastructure, which enables scalable compliance, robust revenue generation, and expanded access to global markets. We expect 2025 to be a transformative year for the company."
2024 Financial Highlights
Net Income: Achieved net income of $887,587, compared to a net loss of $71,077 in 2023.
Earnings Per Share (EPS): Reported EPS of $0.01 for 2024, versus $0.00 in the prior year.
Non-Cash Revenue: Recognized non-cash revenue of $2.6 million for services provided in exchange for marketable securities.
Investment Asset Growth: Increased investment asset value to $1.54 million at year-end 2024, up from $380,000 in 2023.
Capital Structure: Maintained a streamlined capital structure with 87.2 million shares of common stock issued and outstanding.
This financial turnaround reflects early gains from cross-border licensing strategy, regulatory platform scalability, and international manufacturing synergies.
https://www.otcmarkets.com/stock/KRTL/news/KR...?id=471918
KRTL Holding Group, Inc. (OTC: KRTL), a diversified holding company with subsidiaries engaged in pharmaceutical consulting, regulatory compliance, and international commercialization, today reported its financial results for the year ended December 31, 2024, and outlined its strategic roadmap for 2025.
Operational & Strategic Milestones
Strategic Merger Initiated: KRTL Biotech signed a Memorandum of Understanding (MOU) with Bolivia-based Industria QuÃÂmico Farmacéutica Sigma Corp. S.R.L., initiating a formal international merger process and integrated manufacturing expansion.
Regulatory Compliance Strengthened: Maintained FDA registration for KRTL Biotech's operational platform and implemented a robust Quality Management System (QMS), aligning with international regulatory standards.
Market Expansion Efforts: Attracted interest from U.S. and South American pharmaceutical manufacturers seeking entry to the U.S. via KRTL Biotech's compliance infrastructure for faster, regulation-aligned distribution.
Enhanced Internal Capabilities: Expanded internal teams in legal, accounting, and strategic advisory to support governance, licensing, and market entry advisory services.
Looking Ahead â KRTL Strengthens Global Infrastructure
In 2025, KRTL continues to evolve with international production capabilities and scalable regulatory support. The Company's FDA-anchored regulatory foundation, expanding QMS, and growing pharmaceutical network position it to offer high-value services and products, including:
U.S. Market Entry Support: Assisting foreign manufacturers in leveraging KRTL's FDA-registered subsidiary and quality systems for streamlined entry into the U.S. market.
API Sourcing and Oversight: Managing formulation, labeling, and sourcing in partnership with GMP-certified manufacturers in the U.S. and South America, supported by bilateral logistics frameworks and FDA documentation protocols.
Regulatory Consulting & Licensing: Providing strategic regulatory guidance and licensing support to early-stage pharmaceutical and nutraceutical companies, ensuring 21 CFR, DEA, and international compliance alignment.
Revenue-Sharing & Commercialization: Facilitating product commercialization and revenue-sharing partnerships under the KRTL umbrella, including current product launches and licensing structures.
CEO Cesar Herrera commented: "KRTL is creating new opportunities for partners, international consultants, and global investors by actively identifying undervalued assets and leveraging the company's expertise in regulatory and operational frameworks. The company continues to pursue mergers and acquisitions, strategically evaluating and stacking candidates that align with its long-term growth vision. Recent achievements, including FDA registration, implementation of a Quality Management System (QMS), and the merger with SIGMA, validate KRTL's unique infrastructure, which enables scalable compliance, robust revenue generation, and expanded access to global markets. We expect 2025 to be a transformative year for the company."
2024 Financial Highlights
Net Income: Achieved net income of $887,587, compared to a net loss of $71,077 in 2023.
Earnings Per Share (EPS): Reported EPS of $0.01 for 2024, versus $0.00 in the prior year.
Non-Cash Revenue: Recognized non-cash revenue of $2.6 million for services provided in exchange for marketable securities.
Investment Asset Growth: Increased investment asset value to $1.54 million at year-end 2024, up from $380,000 in 2023.
Capital Structure: Maintained a streamlined capital structure with 87.2 million shares of common stock issued and outstanding.
This financial turnaround reflects early gains from cross-border licensing strategy, regulatory platform scalability, and international manufacturing synergies.
